All In Biotech

Drug Trial Radar · NCT00414102

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep Questionnaire - Interactive Voice Response System (PSQ-IVRS) in an "At-Home Setting" in an Adult Population With Chronic Insomnia

Last checked: Nov 20, 2026Latest source record: Jun 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Oct 2006

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the subjective treatment effects of ramelteon, once daily (QD), on sleep using a post sleep questionnaire-interactive voice response system in adults with chronic insomnia.

Conditions

  • Chronic Insomnia

Interventions

  • RamelteonDrug

    Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.

  • PlaceboDrug

    Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average subjective Sleep Latency from Day 15 to Day 21Time frame: Day 22

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Los Angeles Area, California

  • Site not named

    San Diego, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver Area, Colorado

  • Site not named

    Delray Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Boise, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City Area, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Auburn, Maine

  • Site not named

    Baltimore Area, Maryland

  • Site not named

    Washington D.C. Area, Maryland

  • Site not named

    Hattiesburg, Mississippi

  • Site not named

    Saint Louis Area, Missouri

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Long Island City, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Staten Island, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Morganton, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Gallipolis, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Portland Area, Oregon

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.